Satsuma Pharmaceuticals Analysis
What is Satsuma Pharmaceuticals?
Satsuma provides developer infrastructure for real-time blockchain data indexing and querying. Y Combinator describes it as a tool for building applications on top of real-time blockchain data, and LinkedIn says it lets blockchain developers create custom APIs from smart contract data. GitHub references indicate the product later became Alchemy Subgraphs, suggesting a rebrand or acquisition-related transition.
Location
188 King Street, San Francisco, California, United States
Employees
1-10
Founded
2021
Business Model
Research and development of therapeutics; revenue from commercialization and partnerships.
Company Stage
Other
YC Batch
S21
Product Features & Capabilities
- STS101, Dihydroergotamine (DHE) Nasal Powder, Acute treatment of migraine with or without aura, Investigational product, Not yet FDA approved.
Who are the founders of Satsuma Pharmaceuticals
Market Focus
Satsuma Pharmaceuticals primarily focuses on the pharmaceutical industry, specifically in developing innovative therapeutics for the acute treatment of migraines.
Investors
- TPG
- Vivo Capital
- CAM Capital
- Citadel Enterprise Americas
- Commodore Capital
- Cormorant Asset Management
- 16 other unnamed investors
Competitors Overview
Satsuma Pharmaceuticals operates in the migraine treatment market, focusing on innovative therapeutics, particularly their lead product candidate, STS101, a dihydroergotamine nasal powder. The main competitors in this market include:
-
Biohaven Pharmaceuticals: Known for its product, Nurtec ODT (rimegepant), which is an orally dissolving tablet that provides rapid relief from migraines. Its advantage lies in its dual action as both an acute treatment and a preventive therapy.
-
Axsome Therapeutics: Their product, AXS-07, is a novel combination of two existing drugs, which aims to provide faster and more effective relief from migraines. The combination approach may offer a unique advantage in efficacy compared to single-agent therapies.
-
Teva Pharmaceutical Industries: Teva offers Ajovy (fremanezumab), a preventive treatment for migraines. Its advantage is in its long-acting formulation, which allows for monthly or quarterly dosing, appealing to patients looking for less frequent treatment options.
-
Amgen: With Aimovig (erenumab), Amgen provides a preventive treatment that blocks the CGRP receptor, which is involved in migraine pathophysiology. Its advantage is its established efficacy and safety profile in preventing migraines.
-
Zosano Pharma: Their product, Qtrypta, is an intranasal formulation of a triptan, which is designed for rapid absorption and quick relief. This delivery method is similar to Satsuma's STS101, but the specific formulation and delivery technology may differ.
Notable differences among these competitors include the mode of delivery (oral vs. nasal), the mechanism of action (CGRP inhibitors vs. traditional triptans), and the dual-action capabilities of some products, which may provide broader treatment options for patients.
See something that needs updating? Suggest edits to this profile.